Clinical Trial Update: Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating insulin glargine 300 U/mL (Gla-300) and insulin degludec 100 U/mL (IDeg-100) in insulin-naïve adults with type 2 diabetes and renal imp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Impairment
• Type 2 Diabetes Mellitus

Drugs mentioned

• TOUJEO (insulin glargine)
• Tresiba (insulin degludec)

Snippet

Sponsor: Sanofi | Conditions: Type 2 Diabetes Mellitus, Renal Impairment | Phase 4 | Status: TERMINATED | Results posted: 2024-09-05